Global Tuberculosis Drug Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

PART 03: Research Methodology

PART 04: Introduction

• Key market highlights

PART 05: Key pipeline

PART 06: Market landscape

• Market overview
• Market size and forecast
• Five forces analysis

PART 07: High burden countries (HBCs)

• Categorization of HBCs

PART 08: TB diagnostics

• Overview

PART 09: Market segmentation by disease type

• Global latent TB market
• Global active TB market

PART 10: Market segmentation by drug class

• Global first-line anti-TB drugs market
• Global second-line anti-TB drugs market

PART 11: Geographical segmentation

• TB drugs market in Americas
• TB drugs market in EMEA
• TB drug market in APAC

PART 12: Market drivers

• Increase in outbreak of TB-HIV co-infections
• Emergence of MDR-TB and XDR-TB strains
• Increasing incidence of TB in Africa and Asia

PART 13: Impact of drivers

PART 14: Market challenges

• Insufficient demand and high drug cost in developed countries
• Liberal regulations and lack of awareness in developing countries
• Limited diagnostic procedures

PART 15: Impact of drivers and challenges

PART 16: Market trends

• Increased spending on TB diagnostic kits
• Focus on development of shorter TB drug regimens
• Increased focus on TB vaccine development

PART 17: Vendor landscape

• Competitive scenario
• Key news

PART 18: Key vendor analysis

• Lupin
• Otsuka Novel Products
• Pfizer
• Sandoz
• Sanofi
• Other prominent vendors

PART 19: Appendix

• List of abbreviations

PART 20: Explore Technavio